The pharmaceutical company Farmak continues to invest in its development in Ukraine, strengthening its position in the pharmaceutical market. In 2024, the total amount of investments reached UAH 1.7 billion.
More than UAH 957 million was allocated to capital investments, including the implementation of the SAP S/4HANA ERP system for more efficient business process management, modernization of laboratories, warehouse upgrades for product storage, additional equipment for production facilities, and the construction of an innovation center in Kyiv. This center will house production facilities, laboratories, and company offices.
An additional UAH 757 million was directed toward research and development of new pharmaceutical products.
Each year, the company launches up to 20 new products on the market. In 2024, Farmak introduced several important medicines, including a drug for maintaining fluid balance during surgeries, a muscle relaxant for surgical procedures, a treatment for wounds, pressure ulcers, and frostbite, an infusion antibiotic for non-hospital pneumonia therapy, a medication for blood pressure reduction, a pain reliever, and a treatment for angina, among others.
Farmak is the leader in the pharmaceutical market in Ukraine* and operates two production sites in Ukraine, a manufacturing facility in Spain, and 11 international offices and marketing and distribution companies in countries such as Poland, the Czech Republic, Slovakia, the United Kingdom, the UAE, Vietnam, Switzerland, Kazakhstan, Uzbekistan, Kyrgyzstan, and Moldova. Farmak’s products are exported to more than 60 countries worldwide.
*According to Proxima Research, based on pharmaceutical sales volumes in monetary terms in 2024
